about
GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.Prospects for combined use of oncolytic viruses and CAR T-cells.Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.Impact of genomics on the surgical management of melanoma.Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.Next generation of immune checkpoint therapy in cancer: new developments and challenges.Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.Next generation immune-checkpoints for cancer therapy.Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.The Imbalance of FOXP3/GATA3 in Regulatory T Cells from the Peripheral Blood of Asthmatic Patients.Emerging Therapies in the Management of Advanced-Stage Gastric CancerAnti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal EffectsDose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumorsThe Unsolved Jigsaw Puzzle of the Immune Response in Chagas DiseaseInsights Into the Molecular Mechanisms of T Follicular Helper-Mediated Immunity and Pathology
P2860
Q33814776-7E9C619C-DDB2-4C35-8AD1-FF2F4D0BD207Q47103891-164D8DDA-CA95-4004-B901-BEEA332DD4E2Q47198559-0742953D-1EE9-4E8F-9D0E-133AA1E4D97BQ47325431-54AFBFC6-4D96-4B48-96B9-99D7F43A40B7Q47936526-41C9B0A8-8E5A-4D27-8C9A-3DA80D82D0D5Q47986213-B7D9D180-6D33-44BF-B168-BDCB76BF0E2DQ50010320-CE2BDF86-ABD8-427A-BD6C-3CDB66A38E1FQ50545420-E8612CB2-734E-4A89-94BE-90FEF6C2A966Q52653710-E352335D-4FDA-40B8-932F-2F63DBE79E83Q52683991-21A3DF41-50E9-418E-9BA4-103236865721Q55008075-91387753-D420-4848-9115-B4A74B678B96Q55383705-EDC46CF9-A352-472E-9795-7D794823CEAEQ55386131-3AA7B53B-AE2D-47EA-8F5C-6F0FC4D7D6FAQ55712193-8AFF6A36-31F2-495E-83DA-E0D41E3E7D6DQ57111080-0F9D3B70-33C2-461B-9AFD-A274EC39F2F9Q57191719-FDBE5239-98AD-4450-B6E8-948757DB4696Q58698379-5BB4FCC2-7C38-4010-9A5D-90118340BA50Q58705710-A9DD5451-C98B-4E44-BA89-2082FEEEB90FQ58777530-5D3309AA-253E-402C-8284-4CCEB963C8D2
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Rationale for anti-GITR cancer immunotherapy
@ast
Rationale for anti-GITR cancer immunotherapy
@en
Rationale for anti-GITR cancer immunotherapy
@nl
type
label
Rationale for anti-GITR cancer immunotherapy
@ast
Rationale for anti-GITR cancer immunotherapy
@en
Rationale for anti-GITR cancer immunotherapy
@nl
prefLabel
Rationale for anti-GITR cancer immunotherapy
@ast
Rationale for anti-GITR cancer immunotherapy
@en
Rationale for anti-GITR cancer immunotherapy
@nl
P2093
P1476
Rationale for anti-GITR cancer immunotherapy
@en
P2093
Becker Hewes
Deborah A. Knee
Jennifer L. Brogdon
P356
10.1016/J.EJCA.2016.06.028
P407
P577
2016-11-01T00:00:00Z